90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

Summary

This study is for patients with neuroblastoma or a neuroendocrine tumor who have not been able to have standard therapy or have failed the first-line therapy. The purpose of this study is to assess the safety and effectiveness of the combination of retinoic acid and Onalta (Y-90-DOTA-tyr3-Octreotide) in treating neuroblastoma and neuroendocrine tumors.

Timeline

Start

2009-06

Primary completion

2013-11

Completion

2013-11

Drugs

Indications